**COVID-19 Vaccine**

**Training Plan**

**Training Plan – COVID-19 Vaccine**

|  |  |  |
| --- | --- | --- |
| **Training Name: COVID-19 Vaccine** | | |
|  | ❑ **Training** ❑ **Simulation** ❑ **Workshop** 🗹 **Presentation** | |
| ***Training Objectives*** | 1. Attendees will verbalize the importance of the COVID-19 Vaccine in the Long Term Care setting 2. Attendees will describe the process for COVID-19 Vaccine Administration 3. Attendees will verbalize the risks and benefits of the COVID-19 Vaccine 4. Attendees will verbalize immediate follow-up for the COVID-19 Vaccine | |
| ***Connection to Overall Project Goals*** | * This training is part of the overall project to educate and support nursing facility operators and staff regarding the COVID-19 Vaccine in accordance with current CMS, CDC and FDA resources | |
| ***Participants:***  ***Who should attend?*** | For the purposes of this education, we will refer to the CDC and FDA resources for COVID-19 vaccine for employees and residents  Education is offered in slide presentation form with speaker’s notes for use by each facility.  Participants:  Nursing Staff-RN, LPN, Nursing Assistant  Interdisciplinary Team | |
| **What training should they attend before this one?** | * No pre-requisite |
| **What training should they attend after this?** | * Annually, new licensed nurse hire and as needed |
| ***Facilitators:***  ***(How many trainers should participate and whom?)*** | ***One presenter will be needed to facilitate the presentation, discussion and post-test*** | |
| *Logistics Requirements* | *What is needed?* | * Communication slide presentation * Attendance Sheet |
| * Room for training * Projector * Screen or other blank light-colored surface | * Room for training * Projector * Screen or other blank light-colored surface |

**References and Resources**

Centers for Medicare & Medicaid Services. QSO-21-19-NH. Interim Final Rule – COVID-19 Vaccine Immunization Requirements for Residents and Staff. May 11, 2021: <https://www.cms.gov/files/document/qso-21-19-nh.pdf>

Vaccine Adverse Event Reporting System (VAERS). Frequently Asked Questions (FAQs): <https://vaers.hhs.gov/faq.html>

Centers for Disease Control and Prevention. Long-Term Care Facility Toolkit: Preparing for COVID-19 Vaccination at Your Facility: <https://www.cdc.gov/vaccines/covid-19/toolkits/long-term-care/index.html>

Centers for Disease Control and Prevention. Vaccine Storage and Handling Toolkit, March 2021: <https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf>

Centers for Disease Control and Prevention. Updated Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination. Updated Apr. 27, 2021: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html>

Centers for Disease Control and Prevention. What Long-Term Care Facility Residents Need to Know About COVID-19 Vaccination. Updated Apr. 30, 2021: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/LTCF-residents.html>

AMDA COVID-19 Vaccine Education Toolkit can be accessed at:

<https://paltc.org/newsroom/amda-releases-covid-19-vaccine-education-toolkit>

Centers for Medicare & Medicaid Services State Operations Manual, Appendix PP – Guidance to Surveyors for Long Term Care Facilities (Rev. 173, 11-22-17): <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107ap_pp_guidelines_ltcf.pdf>

Centers for Medicare & Medicaid Services, “Nursing Home Reopening Guidelines for State and Local Officials”, May 18, 2020, Revised 03/10/21:

<https://www.cms.gov/files/document/qso-20-30-nh.pdf-0>

Centers for Medicare & Medicaid Services, “Toolkit on State Actions to Mitigate COVID-19 Prevalence in Nursing Homes”, April 2021. Version 21: <https://www.cms.gov/files/document/covid-toolkit-states-mitigate-covid-19-nursing-homes.pdf>

Centers for Medicare and Medicaid Services (CMS) Infection Prevention Critical Element Pathway, Form CMS 20054 (12/2020): <https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/GuidanceforLawsAndRegulations/Nursing-Homes>

Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN) LTCF COVID-19 Module: <https://www.cdc.gov/nhsn/ltc/covid19/index.html>

Centers for Disease Control and Prevention. COVID-19 Vaccination: <https://www.cdc.gov/vaccines/covid-19/index.html>

Vaccine Adverse Event Reporting System (VAERS): <https://vaers.hhs.gov/>

U.S. Food & Drug Administration (FDA). Emergency Use Authorization: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>

Centers for Disease Control and Prevention, Interim Clinical Considerations for Use COVID-19 Vaccines Currently Authorized in the United States. Last Reviewed: May 14, 2021: <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html>

Centers for Disease Control and Prevention. How CDC is Making COVID-19 Vaccine Recommendations. Updated May 14, 2021: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html>

Centers for Disease Control and Prevention. Post Vaccine Considerations for Residents. Updated Mar. 13, 2021: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/post-vaccine-considerations-residents.html>

Centers for Disease Control and Prevention. Different COVID-19 Vaccines. Updated Mar. 13, 2021: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html>

Centers for Disease Control and Prevention. Post-vaccination Considerations for Workplaces, Updated Apr. 2, 2021: <https://www.cdc.gov/coronavirus/2019-ncov/community/workplaces-businesses/vaccination-considerations-for-workplaces.html>

Centers for Disease Control and Prevention. Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination, Mar. 3, 2021: <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html>

Centers for Disease Control and Prevention. COVID-19 ACIP Vaccine Recommendations. Advisory Committee on Immunization Practices (ACIP): <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>

Centers for Disease Control and Prevention. Benefits of Getting a COVID-19 Vaccine. Updated Apr. 12, 2021: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html>

Food and Drug Administration Fact Sheet for Recipients and Caregivers. Emergency Use Authorization (EUA) of the Pfizer-Biontech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older, Revised May 10, 2021: <https://www.fda.gov/media/144414/download>

Food and Drug Administration Fact Sheet for Recipients and Caregivers Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) Revised Mar. 26, 2021: <https://www.fda.gov/media/144638/download>

Food and Drug Administrator Fact Sheet for Recipients and Caregivers. Emergency Use Authorization (EAU) of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 18 Years of Age and Older: <https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-Recipient-fact-sheet.pdf>